Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54.7M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
30M
-
Shares change
-
+16.2K
-
Total reported value, excl. options
-
$280M
-
Value change
-
-$1.23M
-
Put/Call ratio
-
0.35
-
Number of buys
-
37
-
Number of sells
-
-35
-
Price
-
$9.35
Significant Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q1 2022
102 filings reported holding MRNS - Marinus Pharmaceuticals, Inc. - Common Stock as of Q1 2022.
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30M shares
of 54.7M outstanding shares and own 54.73% of the company stock.
Largest 10 shareholders include Lion Point Capital, LP (3.63M shares), VR Adviser, LLC (3.16M shares), Avoro Capital Advisors LLC (3.15M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (2.77M shares), BlackRock Inc. (2.63M shares), 683 Capital Management, LLC (1.93M shares), VANGUARD GROUP INC (1.7M shares), Bain Capital Life Sciences Investors, LLC (1.43M shares), Bleichroeder LP (1.32M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1.26M shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.